Karyopharm Therapeutics Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Karyopharm Therapeutics Stock Summary

Karyopharm Therapeutics competes with Equillium, DiaMedica Therapeutics, Valneva SE, Vivani Medical, and Denali Therapeutics. Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts. Karyopharm Therapeut operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 442 people.

Karyopharm Therapeutics Key Financial Ratios

Karyopharm Therapeutics Key Balance Sheet Accounts

Karyopharm Therapeutics Key Income Statement Accounts

Karyopharm Therapeutics Key Cash Accounts

Karyopharm Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Karyopharm Therapeutics's current stock value. Our valuation model uses many indicators to compare Karyopharm Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Karyopharm Therapeutics competition to find correlations between indicators driving Karyopharm Therapeutics's intrinsic value. More Info.Karyopharm Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Karyopharm Therapeutics' Return On Equity is increasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Karyopharm Therapeutics' earnings, one of the primary drivers of an investment's value.

Karyopharm Therapeutics Systematic Risk

Today, most investors in Karyopharm Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Karyopharm Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Karyopharm Therapeutics growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Karyopharm Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Karyopharm Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Karyopharm Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Karyopharm Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Karyopharm Therapeutics's daily price indicators and compare them against related drivers.

When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.